Original Article

The regioselective glucuronidation of morphine by dimerized human UGT2B7, 1A1, 1A9 and their allelic variants

Zi-zhao YANG1, Li LI2, Lu WANG3, Ling-min YUAN3, Ming-cheng XU1, Jing-kai GU3, Hui-di JIANG1, Lu-shan YU1, *, Su ZENG1, *
1Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; 2Department of Pharmacy, Zhejiang Hospital, Zhejiang Provincial Key Lab of Geriatrics, Hangzhou 310058, China; 3School of Life Sciences, Jilin University, Changchun 130012, China

Abstract
Uridine diphosphate-glucuronosyltransferase (UGT) 2B7 is expressed mostly in the human liver, lung and kidney and can transfer endogenous glucuronide group into its substrate and impact the pharmacological effects of several drugs such as estriol, AZT and morphine. UGT2B7 and its allelic variants can dimerize with the homologous enzymes UGT1A1 and UGT1A9, as well as their allelic variants, and then change their enzymatic activities in the process of substrate catalysis. The current study was designed to identify this mechanism using morphine as the substrate of UGT2B7. Single-recombinant allozymes, including UGT2B7*1 (wild type), UGT2B7*71S (A71S, 211G>T), UGT2B7*2 (H268Y, 802C>T), UGT2B7*5 (D398N, 1192G>A), and double-recombinant allozymes formed by the dimerization of UGT1A9*1 (wild type), UGT1A9*2 (C3Y, 8G>A), UGT1A9*3 (M33T, 98T>C), UGT1A9*5 (D256N, 766G>A), UGT1A1 (wild type) with its splice variant UGT1A1b were established and incubated with morphine in vitro. Each sample was analyzed with HPLC-MS/MS. All enzyme kinetic parameters were then measured and analyzed. From the results, the production ratio of its aberrant metabolism and subsequent metabolites, morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G), changes regioselectively. Double-recombinant allozymes exhibit stronger enzymatic activity catalyzing morphine than the single-recombinant allozymes. Compared to UGT2B7*1, UGT2B7*2 singles or doubles have lower $K_m$ values for M3G and M6G, whereas UGT2B7*5 allozymes perform opposite effects. The double allozymes of UGT1A9*2 or UGT1A9*5 with UGT2B7 tend to produce M6G. Interestingly, the majority of single or double allozymes significantly reduce the ratio of M3G to M6G. The UGT1A9*2-UGT2B7*1 double enzyme has the lowest M3G:M6G ratio, reflecting that more M6G would form in morphine glucuronide metabolism. This study demonstrates that UGT2B7 common SNPs and their dimers with UGT1A1 and UGT1A9 and their allelic variants can regioselectively affect the generation of two metabolites of morphine via altering the $CL_{int}$ ratios of M3G to M6G. These results may predict the effectiveness of morphine antinociception in individualized opioid treatment.

Keywords: UGT2B7; single nucleotide polymorphisms; dimerization; enzyme kinetics; morphine metabolism

Acta Pharmacologica Sinica (2017) 38: 1184–1194; doi: 10.1038/aps.2016.157; published online 29 May 2017

Introduction
As a member of the uridine diphosphate-glucuronosyltransferase (UGT) family, UGT2B7 is expressed mostly in the human liver, lung and kidney and can transfer endogenic glucuronide group into its substrate[1, 2]. This glucuronidation can impact the pharmacological effects of several drugs in vivo such as estriol[3], 3’-azido-deoxythymidine (AZT) and morphine[4]. At the same time, its enzymatic activity can be inhibited by certain chemical compounds, such as ketoconazole[5, 6]. UGT2B7 has many functional variants, some of which have been found among East Asians. It was reported that the UGT2B7*71S (211G>T, A71S) variant was found in 12% of 50 normal genome DNA samples extracted from the blood of healthy South Korean volunteers[7]. In addition, UGT2B7*2 (802C>T, H268Y) showed a frequency of 9.2% in a Chinese population[8], and UGT2B7*5 (1192G>A) was found widely in a Japanese population[9]. However, some variants have the potential to induce serious maladies. For example, individuals with the 161 C>T variant in UGT2B7 may be susceptible to breast cancer[10], and the UGT2B7*2 variant was found to induce tumor of the bladder[11]. UGT1A1*28 (TA 7/7) and *6 (A/A) lead to...
a severe irinotecan-induced toxicity in colorectal carcinoma patients, contributing to an obvious enhancement of the accumulation of its toxic metabolite, SN-38, in patient colon tissues [12, 13]. Therefore, variant UGTs may convert non-toxic drugs or endogenous compounds to toxic metabolites and then give rise to severe diseases.

Recent research has demonstrated that different UGTs and their allelic variants can be co-expressed in same genome of the same person in clinical practice. Mehlotra et al found that Hispanic-Americans can harbor both UGT2B7*71S and UGT1A9*3 [14]. Deng et al analyzed the DNA of 200 Chinese renal transplant recipients and observed that some of them harbor both UGT1A9*3 and UGT2B7*2 [15]. Accordingly, Yuan et al discovered that UGT2B7 can dimerize with its variants and affect enzymatic affinity to its substrates [16]. Liu et al recognized that UGT1A1, UGT1A9 and their variants can dimerize and form oligomers, then change each of their enzymatic activities and regioselectivities involved in quercetin glucuronidation [16, 17]. One hypothesis is that some co-expression of UGT allelic variants in one patient can result in protein–protein interactions (PPI). If this hypothesis is correct, it would alter enzyme-substrate binding mechanisms for each UGT enzyme.

Morphine, a vital analgesic, can be converted to two main glucuronide metabolites, morphine-6-glucuronide (M6G) and morphine-3-glucuronide (M3G) by UGT2B7 (Figure 1). M6G has stronger antinociception and agonist activity on opioid receptors than morphine [18, 19]. In addition, after morphine treatment, the antinociceptive effect of M6G may be antagonized by M3G [20]. Interestingly, the latter one does not contribute to the performance of morphine antinociception [21]. Therefore, to reduce pain, a decreased dose of M3G or an increased dose of M6G would be beneficial. It has been reported that patients with diverse UGT2B7 variants have a different analgesic response to the same dose of morphine [22]. In addition, Sawyer et al investigated that patients suffering pain who carried the UGT2B7 homozygous variant genotype 161C>T displayed lower enzymatic activity in morphine catalysis [23]. All these findings indicated that single-nucleotide polymorphisms (SNPs) of UGT2B7 would be a major factor in morphine glucuronidation.

UGT2B7, UGT1A1 and UGT1A9 are all involved in the process of morphine metabolism [24]. UGT1A1 contributes to M6G generation [25]. As described above, UGT2B7, UGT1A1 and UGT1A9, as well as their allelic variants, can dimerize with each other. These double-recombinant allozymes, which are constructed via a Bac-to-Bac system and acquired from sf9 cells, can change their affinities between UGT2B7 and zidovudine [16, 17]. This means the dimerization produced in vivo between each UGT enzyme would be another vital element intervening in the process of morphine metabolism.

To verify these hypotheses, in the present study, we analyzed the regioselectivity for morphine glucuronidation under the influence of common UGT2B7 SNP variants in a population and their dimers with UGT1A1 and UGT1A9 as well as their allelic variants. We then determined all the enzyme kinetic parameters of M3G and M6G production catalyzed by each single or double recombinant allozyme. The complete results were reviewed and used for specific analyses.

**Materials and methods**

**Materials and reagents**

Plasmids with UGT2B7 *1 (wild type), *71S (A71S, 211G>T), *2 (H268Y, 802C>T), *5 (D398N, 1192G>A); UGT1A9*1 (wild type), UGT1A9*2 (C3Y, 8G>A), UGT1A9*3 (M33T, 98T>C), UGT1A9*5 (D256N, 766G>A), and UGT1A1 (wild type) with its splicing variant UGT1A1b were constructed and ligated to the pFastBac vector before all genes were connected with HA or CFP tags, which are convenient for the detection of their interactions.

**Figure 1.** The allelic variant gene structures of UGT2B7 and a schematic diagram of morphine metabolism.
expression. Then, all the plasmids were verified by double digestion and sequenced previously\(^{[16,17]}\). In brief, all vectors were transferred to E. coli DH10a-competent cells for the acquisition of recombinant bacmid plasmids. UGT2B7, UGT1A1 and UGT1A9 plasmids were double-transfected into sf9 cells. Baculovirus was then collected on the third passage (all titers were more than 108 pfu/mL). After fluorescence resonance energy transfer (FRET) assays and co-immunoprecipitation (Co-IP) analyses, all allozymes were used as functional proteins\(^{[16,17]}\).

Morphine, M3G and M6G were obtained from Cerilliant Corporation (Round Rock, TX, USA). M6G-d3 was labeled by Biomag System Company (Changshu, China). UDPGA were purchased from Sigma Chemical Co (St Louis, MO, USA). The BCA assay kit was purchased from Sangon Biotech Company (Changshu, China). Tris-HCl, NaCl, EDTA, MgCl\(_2\), perchloric acid and KH\(_2\)PO\(_4\) were purchased from Sinopharm Chemical (Shanghai, China). Tris-HCl, NaCl, EDTA, MgCl\(_2\), perchloric acid and KH\(_2\)PO\(_4\) were purchased from Sinopharm Chemical (Beijing, China). Alamethicin was obtained from Sigma-Aldrich Company (Shanghai, China). HPLC-grade methanol and formic acid were purchased from Tedia Corporation (Round Rock, TX, USA). Ultrapure water (18.2 MΩ) was prepared using an ELGA PureLab Ultra system (High Wycombe, UK).

**Incubation assay**

The incubation mixture (100 μL total volume) consisted of 50 mmol/L potassium phosphate buffer (pH 7.4), 5 mmol/L MgCl\(_2\), 10mmol/L UDPGA, 0.1 mg/mL total recombinant proteins, alamethicin (50 μg/mg of protein based on the concentration of each allozyme) and 1-200 μmol/L morphine. The optimum conditions (protein concentration and incubation time) were ascertained by preliminary experiments. Then, the reaction was initiated by adding 5 μL of 10 mmol/L UDPGA to concentrations of 500 μmol/L in final 100 μL volume solutions following a 5 min preincubation at 37 °C. The incubation was performed at 37 °C for 50 min. The reaction was terminated by adding 200 μL of acetonitrile and spiked M6G-d3 as the internal standard at a final concentration of 10 ng/mL. After vortex and vibration, the mixture was centrifuged at 12 000×g for 15min, and the supernatants were then evaporated and dried in a centrifugal thickener (Labconco, USA). Residues were dissolved in a 100μL mobile phase (A) methanol: (B) 0.5% formic acid and purified water solution (2:98, v/v) by vortex. A 10 μL sample was injected into HPLC-MS/MS for further analysis.

**Determination of morphine glucuronides**

Agilent 1290 infinity LC system equipped with a G4220A quaternary pump, G4226A auto sampler, and G1330B 1290 thermostat; AB SCIEX 4000 plus triple quadrupole mass spectrometer (AB SCIEX Technologies) included an electrospray ionization source were performed for the HPLC-MS/MS analysis. The auto sampler was maintained at 4 °C, and the temperature for column compartment was set at 30 °C. Chromatographic separations were achieved on an Agilent HILIC PLUS SB-C18 column (2.1 mm×50 mm, 3.5 μm). The mobile phase for simultaneously analyzing M3G and M6G with deuterated internal standard M6G-d3 (ISTD) consisted of the solutions we referred previously. The separation method was applied via a gradient elution mode of 95% A and 5% B at 0–1 min, 2% A and 98% B at 1–6 min, 95% A and 5% B at 6–7 min with a flow rate of 0.25 mL/min.

The mass spectrometer with an ESI source was operated in positive ionization mode. The mass spectrometer parameters were set as following: collision energy, 43 eV for M3G, M6G and M6G-d3 (ISTD); declustering potential, 85 V for all the three compounds; integral temperature of drying gas, 350 °C; drying gas flow, 8 L/min; temperature for ionization 550 °C. Data were acquired using Analyst 1.5.2 (AB SCIEX) in multiple reaction monitoring (MRM) mode by recording ion currents for the following transitions: m/z 462.1–286.1 for M3G and M6G, m/z 465.1–289.1 for M6G-d3 (ISTD). The method was fully validated according to the US FDA guidelines (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM368107.pdf).

**Kinetic data analyses**

The kinetic parameters were analyzed using GraphPad Prism, version 6.0 (GraphPad Software Inc, San Diego, CA, USA). The enzymatic kinetic parameters such as \(V_{\text{max}}\) and \(K_m\) for morphine glucuronidation were estimated by analyzing the Michaelis–Menten equation:

\[
V = V_{\text{max}} [S] / (K_m + [S])
\]

where \(V\) is the velocity of the reaction, \([S]\) is the substrate concentration, \(K_m\) is the Michaelis–Menten constant, and \(V_{\text{max}}\) is the maximum velocity. \(C_{\text{lin}}\) is the intrinsic clearance. Each value was determined as the ratio of \(V_{\text{max}} / K_m\).

**Statistical analysis**

The data were expressed as the mean±standard deviation (SD) of at least three independent experiments in triplicate. The significant differences between the experimental groups were determined using the one-way analysis of variance (ANOVA) followed by a Dunnett’s post hoc test (SPSS 13.0 software, SPSS Inc, Chicago, IL, USA). A value of \(P<0.05\) was considered statistically significant.

**Results**

**Kinetics analysis of morphine glucuronides catalyzed by four UGT2B7 SNPs**

Human of UGT2B7*1 (wildtype) enzymes and three sense variants, *71S (A71S, 211G>T), *2 (H268Y, 802C>T), and *5 (D398N, 1192G>A) (Figure 1) were established and characterized and then used in vitro assay of morphine incubation \(^{[16]}\). The results showed decreasing trends in the \(K_m\) values of UGT2B7*5-HA to M3G and M6G by 31.39% and 15.41%, respectively, compared to HA-tagged UGT2B7*1. However, UGT2B7*2-HA had an opposite effect, in which the \(K_m\) value to M3G increased by 89.83%, and that to M6G increased by 123.4% compared to HA-tagged UGT2B7*1 (Figure 2, Table 1). In addition, the \(C_{\text{lin}}\) ratios of M3G to M6G mediated by UGT2B7*2 and UGT2B7*5 were all lower than those of other
single allozymes.

Kinetics analysis of morphine glucuronides catalyzed by recombinant UGT2B7 allozymes with its allelic variants

To further determine whether the dimerization of UGT2B7 and each of its allelic variants could impact the metabolism of morphine, all double allozymes were prepared and tested. The results indicated $K_m$ values of UGT2B7*5-HA mediated double

![Figure 2. Common SNPs of UGT2B7 single allozymes mediate the glucuronide metabolism of morphine. The Michaelis–Menten kinetic equation shows the enzymatic reaction curves for (A) M3G; (B) M6G.](image)

![Figure 3. UGT2B7*N-UGT2B7*N double allozymes mediate the glucuronide metabolism of morphine. The Michaelis–Menten kinetic equation shows the enzymatic reaction curves for (A) M3G; (B) M6G.](image)

Table 1. Kinetic parameters for morphine-3-glucuronide and morphine-6-glucuronide catalyzed by UGT2B7*N single recombinant allozymes.

| UGT2B7*N  | $K_m$ (µmol/L) | $V_{max}$ (pmol·min$^{-1}$·mg$^{-1}$·protein) | $CL_{int}$ (µL·min$^{-1}$·mg$^{-1}$·protein) | $CL_{int}(M3G)/%$ of 2B7*1HA | $CL_{int}(M6G)/%$ of 2B7*1HA |
|-----------|----------------|--------------------------------------------|---------------------------------------------|-------------------------------|-------------------------------|
| M3G       | M6G            | M3G            | M6G            | M3G         | M6G            | M3G         | M6G            |
| UGT2B7*1-HA | 33.93±9.004  | 55.10±12.40   | 358.7±31.12    | 324.4±28.26 | 10.57          | 5.887        | 1.795        | 100.0          | 100.0          |
| UGT2B7*1-CFP | 29.78±5.759  | 42.49±6.399   | 328.7±19.85    | 282.0±15.02 | 11.04          | 6.637        | 1.663        | 104.4          | 112.7          |
| UGT2B7*7S-HA | 36.06±8.092  | 66.07±16.66   | 494.5±37.06    | 337.6±35.12 | 13.71          | 5.110        | 2.683        | 129.7          | 86.80          |
| UGT2B7*7S-CFP | 32.29±6.169  | 54.43±9.753   | 429.3±26.35    | 421.8±29.15 | 13.30          | 7.749        | 1.716        | 125.8          | 131.6          |
| UGT2B7*2-HA | 64.41±11.14** | 75.81±12.30** | 1772±125.3**   | 1522±106.9** | 27.51**        | 20.08**      | 1.370        | 260.3          | 341.1          |
| UGT2B7*2-CFP | 57.55±9.407** | 71.75±11.81** | 1444±92.77**   | 1486±103.8** | 25.09**        | 20.71**      | 1.211        | 237.4          | 351.8          |
| UGT2B7*5-HA | 23.28±3.728** | 28.70±4.436** | 1769±81.07**   | 1525±72.68** | 75.99**        | 53.14**      | 1.430        | 718.9          | 902.7          |
| UGT2B7*5-CFP | 17.29±2.855** | 20.10±4.250** | 1718±72.90**   | 1604±92.04** | 99.36**        | 79.80**      | 1.245        | 940.0          | 1356           |

Kinetics analysis of common SNPs of UGT2B7 mediate the glucuronide metabolism of morphine. Data are the means±SD of three independent determinations, the asterisks indicate differences that are statistically significant compared to 2B7*1HA (**P<0.01; ***P<0.05).
Table 2. Kinetic parameters for morphine-3-glucuronide and morphine-6-glucuronide catalyzed by UGT2B7*N-UGT2B7*N double recombinant allozymes.

| UGT2B7*N-UGT2B7*N | $K_m$ (µmol/L) | $V_{max}$ (pmol/min/mg protein) | $CL_{int}$ (µL/min/mg protein) | $CL_{int}$ (M3G)/% of 2B7*1HA |
|---------------------|-------------|-------------------------------|-------------------------------|-------------------------------|
|                     | M3G         | M6G                           | M3G                           | M6G                           |
| UGT2B7*1-CFP         | 18.80±2.304** | 20.59±3.687**                 | 1319±42.82**                  | 1195±58.59**                  |
| UGT2B7*2-CFP         | 47.25±6.493*  | 50.59±9.884                   | 2139±107.99**                 | 1926±141.44**                 |
| UGT2B7*5-CFP         | 15.93±3.132** | 16.03±3.634**                 | 1269±62.21**                  | 946.4±53.63**                 |
| UGT2B7*7S-CFP        | 54.93±9.426** | 55.41±7.584                   | 3131±207.8**                  | 2435±129.3**                  |
| UGT2B7*1-HA          | 18.55±6.318** | 18.31±4.345**                 | 1506±92.56**                  | 1258±78.34**                  |
| UGT2B7*2-HA          | 44.29±6.318** | 38.49±5.139**                 | 2986±148.5**                  | 208±91.61**                  |

Kinetics analysis of UGT2B7*N-UGT2B7*N double recombinant allozymes mediate the glucuronide metabolism of morphine. Data are the mean±SD of three independent determinations, the asterisks indicate differences that are statistically significant compared to 2B7*1HA: *P<0.05; **P<0.01.

Allozymes to M3G or M6G declined substantially compared to HA-tagged UGT2B7*1 single allozyme (Figure 3, Table 2). In contrast, that of UGT2B7*2-2B7*5 double allozymes increased clearly to M3G, but not M6G. Notably, UGT2B7*2-UGT2B7*5 double allozymes showed a moderate $K_m$ value to M3G and M6G compared to those of UGT2B7*2-dependent singles or doubles. The $K_m$ and $CL_{int}$ of UGT2B7*7S doubles were slightly upregulated to both M3G and M6G compared to UGT2B7*1. However, $CL_{int}$ ratios of M3G to M6G mediated by UGT2B7 with its variants in double allozymes were all lower than those of their single variants.

Kinetics analysis of morphine glucuronides catalyzed by recombinant allozymes of UGT2B7 and UGT1A1

UGT1A1 and its alternatively spliced variant, UGT1A1b, dimerized with UGT2B7 and its allelic variants. In our test, we found that double allozymes formed between UGT1A1 or UGT1A1b and UGT2B7*N (including wildtype UGT2B7*1 and three variants, UGT2B7*7S, UGT2B7*2 and UGT2B7*5) showed relatively stronger enzymatic activities to catalyze morphine compared to UGT2B7*N singles (Figure 4, Table 3 and 4). The $K_m$ values of UGT1A1b double allozymes were all lower than those of UGT1A1 mediated ones. Although the $K_m$ values of M3G and M6G obtained from the double allozymes of UGT2B7*5 and UGT1A1 or UGT1A1b were slightly lower than the others, the $CL_{int}$ for all double allozymes consisting of UGT2B7*N and UGT1A1 or UGT1A1b were almost the same. In addition, the $CL_{int}$ ratio of M3G to M6G for the double of UGT1A1b-UGT2B7*2 was higher than that of the UGT2B7*2 single allozyme, which indicated that UGT1A1b played a minor role in forming M6G than UGT2B7*2. Compared to UGT2B7 double allozymes, UGT1A1 and UGT1A1b double allozymes exhibited relatively lower ratios of $CL_{int}$ for the formations of M6G.

Kinetics analysis of morphine glucuronides catalyzed by recombinant allozymes of UGT2B7 and UGT1A9

Double allozymes of UGT1A9*2, *3, *5 and UGT2B7 with their allelic variants were used to perform the test. From the results, the affinities of UGT1A9*2 and UGT1A9*5 double allozymes to morphine were found to be much higher than those of UGT1A9*1 and UGT1A9*3 (Figure 5 and 6; Table 5–8). In addition, UGT1A9*2 and UGT1A9*5 mediated double allozymes tended to generate M6G based on the $CL_{int}$ ratios of the two metabolites. UGT1A9*3-UGT2B7*N double allozymes had much higher $CL_{int}$ ratios of M3G to M6G which illustrated that they owned higher enzymatic activities to catalyze morphine and form M6G than UGT1A9*3 single. Notably, the $CL_{int}$ ratio of UGT1A9*2-UGT2B7*1 double allozymes had the lowest value (only 0.9014) among all the singles or doubles, which could be attributed to an increase in the formation of M6G.

Discussion

In this study, we used single or double UGT2B7, UGT1A1, UGT1A9 recombinant allozymes to incubate morphine in vitro and then quantified M3G and M6G to investigate the connections between SNPs or dimerization-induced UGT2B7 enzymatic activity changes and the regioselectivity for morphine glucuronidation. In addition, morphine antinociception and the $CL_{int}$ of M6G formed by single or double allozymes was also explored.

For single allozymes of UGT2B7 including its three allelic variants *2, *7S and *5, they had higher enzymatic activities to catalyze morphine and form M3G and M6G than UGT2B7*1 from the values of $CL_{int}$. However, the $K_m$ values to each metabolite were different from that. There was a predominant increase trend from $K_m$ values of UGT2B7*2 to each M3G or M6G compared to UGT2B7*1. In contrast, UGT2B7*5 exhibited a reverse character. Since we found codons 71 and 268
of UGT2B7 are both located in the substrate binding domain, whereas the highly conserved codon 398 was located in the latter half of the UDPGA-binding domain. These variant sites may lead to differentials of glucuronidation generated in each substrate. Wang et al have used UGT2B7*1, *71S and *2 to metabolize flurbiprofen (FFP) racemate and generate S- and R-FFP glucuronide metabolites. They observed UGT2B7*2 predominated to generate R-FFP glucuronide. From this example, we found the UGT2B7*2 (H268Y, 802C>T) variant may result in regioselectively changing of its substrates’ metabo-

Table 3. Kinetic parameters for morphine-3-glucuronide and morphine-6-glucuronide catalyzed by UGT1A1-UGT2B7*N double recombinant allozymes.

| UGT1A1 | K_m (µmol/L) | V_max (pmol·min⁻¹·mg⁻¹ protein) | CL_int (µL·min⁻¹·mg⁻¹ protein) | CL_int (M3G)/% of 2B7*1HA |
|--------|--------------|-------------------------------|-------------------------------|----------------------------|
| UGT1A1-CFP-UGT2B7*N | 15.55±2.364** | 1795±67.43'' | 1768±80.68'' | 115.4'' 91.11'' 1.459 1092 1344 |
| UGT1A1-CFP-UGT2B7*1-HA | 18.97±3.297** | 2010±92.88'' | 1939±122.7'' | 106.0'' 71.21'' 1.489 1003 1210 |
| UGT1A1-CFP-UGT2B7*71S-HA | 21.45±3.040* | 2004±78.93'' | 2059±119.7'' | 93.63'' 64.40'' 1.451 883 1094 |
| UGT1A1-CFP-UGT2B7*2-HA | 14.06±2.333'' | 1625±64.17'' | 1753±103.2'' | 115.6'' 83.60'' 1.383 1094 1420 |

Kinetics analysis of UGT1A1-UGT2B7*N double recombinant allozymes mediate the glucuronide metabolism of morphine. Data are the mean±SD of three independent determinations, the asterisks indicate differences that are statistically significant compared to 2B7*1HA (*P<0.05; **P<0.01).
Moreover, we noticed that UGT2B7*5 (D398N, 1192G>A) showed lower \(K_m\) values when it catalyzed morphine and generated M3G and M6G compared to the other singles, which suggests that the codon 398 variants may mainly increase the binding of enzyme substrates. Additionally, the affinities of Table 4. Kinetic parameters for morphine-3-glucuronide and morphine-6-glucuronide catalyzed by UGT1A1b-UGT2B7*N double recombinant allozymes.

| UGT1A1b-UGT2B7*N  | \(K_m\) (µmol/L) | \(V_{max}\) (pmol·min\(^{-1} \cdot \text{mg}^{-1} \cdot \text{protein}) | \(CL\int\) (µL·min\(^{-1} \cdot \text{mg}^{-1} \cdot \text{protein}) | \(\text{CL}_{int}(\text{M3G})/ \% \text{ of } 2B7^*1\text{HA} \) |
|-------------------|-----------------|------------------------|-------------------|------------------------|
| UGT1A1b-CFP-2B7*1-HA | 28.57±4.744 | 26.39±4.910** | 2403±122.8** | 1518±48.2** | 84.11** | 57.52** | 1.462 | 795.7 | 977.1 |
| UGT1A1b-CFP-2B7*1-HA | 32.71±5.229 | 36.74±5.956** | 1837±94.77** | 1207±65.78** | 56.16** | 32.85** | 1.710 | 531.3 | 558.0 |
| UGT1A1b-CFP-2B7*2-HA | 37.61±7.334 | 49.76±9.057 | 2108±139.3** | 1485±101.0** | 56.05** | 29.84** | 1.878 | 530.3 | 506.9 |
| UGT1A1b-CFP-2B7*5-HA | 22.66±4.575* | 22.41±4.898** | 1881±107.7** | 1283±79.15** | 83.01** | 57.25** | 1.450 | 366.3 | 972.5 |

Kinetics analysis of UGT1A1b-UGT2B7*N double recombinant allozymes mediate the glucuronide metabolism of morphine. Data are the mean±SD of three independent determinations, the asterisks indicate differences that are statistically significant compared to 2B7*1HA (* \(P<0.05\); ** \(P<0.01\)).

![Figure 5](image_url1)

Figure 5. UGT1A9*1-UGT2B7*N and UGT1A9*2-UGT2B7*N double allozymes mediate the glucuronide metabolism of morphine. The Michaelis–Menten kinetic equation shows the enzymatic reaction curves for (A, B) M3G; (C, D) M6G.
CL\textsubscript{int} values for both M3G and M6G compared to UGT2B7 wild type single allozyme. After oligomerizing with UGT2B*5, the enzymatic activities of UGT2B7*1 or UGT2B7*71S were activated, but their activities took an opposite reaction after interacting with UGT2B7*2. The integral alteration tends for \( K_m \) values of UGT2B7*2 or UGT2B7*5 to morphine were almost the same as zidovudine\(^{[16]} \). In addition, the \( K_m \) to M3G and M6G was diminished during the catalysis by the UGT2B7*2-
Table 6. Kinetic parameters for morphine-3-glucuronide and morphine-6-glucuronide catalyzed by UGT1A9*2-UGT2B7*N double recombinant allozymes.

| UGT1A9*2-UGT2B7*N | \(K_m\) (µmol/L) | \(V_{max}\) (pmol·min\(^{-1}\)·mg\(^{-1}\) protein) | \(CL_{int}\) (µL·min\(^{-1}\)·mg\(^{-1}\) protein) | \(CL_{int} (M3G)/CL_{int} (M6G)\) | % of 2B7*1HA |
|-------------------|------------------|---------------------------------|---------------------------------|----------------------------|----------------|
| -UGT1A9*2-CFP     | 29.63±3.937      | 19.34±3.161**                   | 2200±91.15**                    | 74.25**                    | 0.9014         | 702.5          | 1399           |
| -UGT2B7*1-HA      | 34.48±5.827      | 25.89±3.624**                   | 2568±143.7**                    | 75.00**                    | 1.147          | 709.6          | 1111           |
| -UGT1A9*2-CFP     | 56.03±12.57**    | 41.48±7.671*                    | 3079±269.2**                    | 54.95**                    | 1.404          | 519.9          | 665.0          |
| -UGT2B7*2-HA      | 24.47±4.658**    | 18.56±3.669**                   | 2284±126.7**                    | 101.6**                    | 1.250          | 961.2          | 1380           |

Kinetics analysis of UGT1A9*2-UGT2B7*N double recombinant allozymes mediate the glucuronide metabolism of morphine. Data are the mean±SD of three independent determinations, the asterisks indicate differences that are statistically significant compared to 2B7*1HA (*\(P<0.05\); **\(P<0.01\)).

Table 7. Kinetic parameters for morphine-3-glucuronide and morphine-6-glucuronide catalyzed by UGT1A9*3-UGT2B7*N double recombinant allozymes.

| UGT1A9*3-UGT2B7*N | \(K_m\) (µmol/L) | \(V_{max}\) (pmol·min\(^{-1}\)·mg\(^{-1}\) protein) | \(CL_{int}\) (µL·min\(^{-1}\)·mg\(^{-1}\) protein) | \(CL_{int} (M3G)/CL_{int} (M6G)\) | % of 2B7*1HA |
|-------------------|------------------|---------------------------------|---------------------------------|----------------------------|----------------|
| -UGT1A9*3-CFP     | 43.96±6.959*     | 39.60±6.245**                   | 3360±190.4**                    | 74.43**                    | 1.728          | 723.1          | 751.1          |
| -UGT2B7*1-HA      | 47.19±8.718*     | 46.73±9.841*                    | 3422±231.9**                    | 72.52**                    | 1.664          | 686.1          | 740.1          |
| -UGT1A9*3-CFP     | 49.06±6.343*     | 49.01±9.100*                    | 3642±175.1**                    | 74.24**                    | 1.750          | 702.4          | 720.6          |
| -UGT2B7*2-HA      | 29.01±4.053      | 21.09±3.808**                   | 2313±99.98**                    | 79.73**                    | 1.107          | 754.3          | 1223           |

Kinetics analysis of UGT1A9*3-UGT2B7*N double recombinant allozymes mediate the glucuronide metabolism of morphine. Data are the mean±SD of three independent determinations, the asterisks indicate differences that are statistically significant compared to 2B7*1HA (*\(P<0.05\); **\(P<0.01\)).

Table 8. Kinetic parameters for morphine-3-glucuronide and morphine-6-glucuronide catalyzed by UGT1A9*5-UGT2B7*N double recombinant allozymes.

| UGT1A9*5-UGT2B7*N | \(K_m\) (µmol/L) | \(V_{max}\) (pmol·min\(^{-1}\)·mg\(^{-1}\) protein) | \(CL_{int}\) (µL·min\(^{-1}\)·mg\(^{-1}\) protein) | \(CL_{int} (M3G)/CL_{int} (M6G)\) | % of 2B7*1HA |
|-------------------|------------------|---------------------------------|---------------------------------|----------------------------|----------------|
| -UGT1A9*5-CFP     | 26.03±4.453      | 23.55±4.242**                   | 2020±102.9**                    | 77.60**                    | 1.149          | 734.2          | 1147           |
| -UGT2B7*1-HA      | 29.36±3.938      | 24.47±4.555**                   | 2095±87.31**                    | 71.36**                    | 1.061          | 675.1          | 1142           |
| -UGT1A9*5-CFP     | 30.77±6.448      | 27.41±4.998**                   | 2245±148.6**                    | 72.96**                    | 1.114          | 690.3          | 1113           |
| -UGT2B7*2-HA      | 22.97±5.130      | 17.27±4.430**                   | 2108±134.1**                    | 91.77**                    | 1.111          | 868.2          | 1403           |

Kinetics analysis of UGT1A9*5-UGT2B7*N double recombinant allozymes mediate the glucuronide metabolism of morphine. Data are the mean±SD of three independent determinations, the asterisks indicate differences that are statistically significant compared to 2B7*1HA (*\(P<0.05\); **\(P<0.01\)).
UGT2B7*5 double allozyme compared to the UGT2B7*2-HA single. As a result, UGT2B7*5 was an active allelic variant during morphine glucuronidation, but UGT2B7*2 was not.

The alternatively spliced variant of UGT1A1b has a frame shift mutation in intron 4 (from I1089 to I1122) of UGT1A1 between 1302bp and 1303bp which alters the C-terminal structure compared to the UGT1A1 wild type. We observed that the enzymatic activity of UGT1A1b declined remarkably compared to that of UGT1A1 due to a mutation that disrupted the hydrophobic packing of the protein. Similar results were obtained for the double allozymes formed by UGT1A1 or UGT1A1b with UGT2B7*N. It is notable that compared to UGT2B7*N-UGT2B7*N double allozymes, UGT1A1 or UGT1A1b and UGT2B7*N double allozymes had noticeably lower \( K_m \) values for M3G or M6G.

All single-expressed UGT2B7 and its variant allozymes showed higher \( \text{CL}_{\text{int}} \) values for M3G and M6G than UGT1A9 wild type-related double allozymes in morphine glucuronidation did. For example, the UGT1A9*2-UGT2B7*1 double allozyme exhibited 2.09- and 1.41-fold higher clearance of M6G and M3G, respectively, compared to the UGT1A9*1-UGT2B7*1 double allozyme. Concurrently, the \( \text{CL}_{\text{int}} \) values of M3G and M6G from UGT2B7*5-UGT1A9*N-formed double allozymes were much higher than those of the other UGT2B7*N-UGT1A9*N doubles. In contrast, UGT2B7*2 and UGT1A9*N double allozymes had fewer changes in \( \text{CL}_{\text{int}} \) values, excepting for a sharp decrease in the \( \text{CL}_{\text{int}} \) of the UGT1A9*2-UGT2B7*2 double allozyme. Since UGT1A9*2 exhibited a 1.66-fold higher enzymatic activity to catalyze mycophenolic acid glucuronidation than UGT1A9*1, so the mutant of UGT1A9*2(C3Y, 8G>A) would be an active variant in UGT1A9.”

UGT subtypes including UGT1A9, UGT1A10, UGT2B7, UGT2B15, and UGT2B17 can stereo-selectively catalyze the glucuronidation of substrates and affect their metabolites’ pharmacological effects. However, there was no report on whether morphine antinociception can be enhanced via the selective alteration of its metabolite ratios by UGT2B7 allelic variants or dimerized with other UGTs. In our study, the \( \text{CL}_{\text{int}} \) ratios of M3G to M6G for single or double allozymes were measured and analyzed. Since M6G has stronger antinociception effects than M3G, as we described previously, a single or double allozyme with a low \( \text{CL}_{\text{int}} \) ratio of M3G to M6G would improve morphine during analgesic treatment. Compared to the \( \text{CL}_{\text{int}} \) ratio of M3G to M6G in the UGT2B7*1 single allozyme (1.795 and 1.663 for HA- and CFP-tagged UGT2B7*1, respectively), UGT1A9*2-UGT2B7*1 double allozyme exhibited the lowest ratio (0.9014), which indicates that morphine can be converted more M6G under such conditions.

In conclusion, UGT2B7 common SNPs and their dimers with UGT1A1 and UGT1A9 and their allelic variants can regioselectively affect the generation of two metabolites of morphine via altering the \( \text{CL}_{\text{int}} \) ratios of M3G to M6G. These results may predict the effectiveness of morphine antinociception in individualized opioid treatment.

**Acknowledgements**

This study was supported by the International Science & Technology Cooperation Program of China (No 2014DFE30050); Program for Zhejiang Leading Team of S&T Innovation Team (No 2011R50014); Natural Science Foundation of Zhejiang Province (No LQ15H310003); and Fundamental Research Funds for the Central Universities of China Ministry of Education (No 2016ZZXX001-08).

**Author contribution**

Zi-zhao YANG, Li LI, Lu WANG, Ling-min YUAN, Ming-cheng XU, Jing-kai GU, Hui-di JIANG, Lu-shan YU, and Su ZENG participated in research design; Zi-zhao YANG, Li LI, and Ling-min YUAN conducted experiments; Zi-zhao YANG, Li LI, and Lu WANG performed data analysis; Zi-zhao YANG and Su ZENG wrote or contributed to the writing of the manuscript.

**Abbreviation**

UGT, uridine diphosphate-glucuronosyltransferase; M3G, morphine-3-glucuronide; M6G, morphine-6-glucuronide; SNPs, single nucleotide polymorphisms; UDPGA, uridine diphosphate glucuronic acid; HA tag, human influenza hemagglutinin tag; CFP tag, enhanced green fluorescent protein C; FRET, fluorescence resonance energy transfer; Co-IP, co-immunoprecipitation.

**References**

1. Ekström L, Johansson M, Rane A. Tissue distribution and relative gene expression of UDP-glucuronosyltransferases (2B7, 2B15, 2B17) in the human fetus. Drug Metab Dispos 2013; 41: 291–5.

2. Sadeque AI, Usmani KA, Palamar S, Cerny MA, Chen W. Identification of human UDP-glucuronosyltransferases involved in N-carbamoyl glucuronidation of forcaserin. Drug Metab Dispos 2012; 40: 772–8.

3. Gall WE, Zawada G, Mojarrabi B, Tephly TR, Green MD, Coffman BL, et al. Differential glucuronidation of bile acids, androgens and estrogens by human UGT1A3 and 2B7. J Steroid Biochem Mol Biol 1999; 70: 101–8.

4. Bélinger AS, Caron P, Harvey M, Zimmerman PA, Mehlotra RK, Guillemette C. Glucuronidation of the antitretoviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab Dispos 2009; 37: 1793–6.

5. Takeda S, Kitajima Y, Ishii Y, Nishimura Y, Mackenzie PI, Oguri K, et al. Inhibition of UDP-glucuronosyltransferase 2b7-catalyzed morphine glucuronidation by ketoconazole: dual mechanisms involving a novel noncompetitive mode. Drug Metab Dispos 2006; 34: 1277–82.

6. Nagaoka K, Hanioka N, Ikushiro S, Yamano S, Narimatsu S. The effects of N-glycosylation on the glucuronidation of zidovudine and morphine by UGT2B7 expressed in HEK293 cells. Drug Metab Pharmacokinet 2012; 27: 388–97.

7. Hwang MS, Lee SJ, Jeong HE, Lee S, Yoo MA, Shin JG. Genetic variations in UDP-glucuronosyltransferase 2B7 gene (UGT2B7) in a Korean population. Drug Metab Pharmacokinet 2010; 25: 398–402.

8. Lin GF, Guo WC, Chen JG, Qin YQ, Goika K, Xiang CQ, et al. An association of UDP-glucuronosyltransferase 2B7 C802T (His268 Tyr) polymorphism with bladder cancer in benzidine-exposed workers in China. Toxicol Sci 2005; 85: 502–6.
9 Saeki M, Saito Y, Jinno H, Tanaka-Kagawa T, Ohno A, Ozawa S, et al. Single nucleotide polymorphisms and haplotype frequencies of UGT2B4 and UGT2B7 in a Japanese population. Drug Metab Dispos 2004; 32: 1048–54.

10 Sawyer MB, Pituskin E, Damaraju S, Bies RR, Vos LJ, Prado CM, et al. A uridine glucuronyltransferase 2B7 polymorphism predicts epirubicin clearance and outcomes in early-stage breast cancer. Clin Breast Cancer 2016; 16: 139–44.

11 Zimmermann A, Blaszkewicz M, Roth G, Seidel T, Dietrich H, Xu JM, Wang Y, Ge FJ, Lin L, Liu ZY, Sharma MR, Saeki M, Saito Y, Jinno H, Tanaka-Kagawa T, Ohno A, Ozawa S, Cruz JE, Saksena R, Jabbour SK, Nosher JL, Hermes-DeSantis E, Moss Mehlotra RK, Bockarie MJ, Zimmerman PA. Prevalence of UGT1A9.

12 Deng XY, Wang CX, Wang XD, Bi HC, Chen X, Li JL, Yuan L, Qian S, Xiao Y, Sun H, Zeng S. Homo- and hetero-dimerization.

13 Liu YQ, Yuan LM, Gao ZZ, Xiao YS, Sun HY, Yu LS, De Gregori S, De Gregori M, Ranzani GN, Allegri M, Minella C, Regazzi Frances B, Gout R, Monserrat B, Cros J, Zajac JM. Further evidence.

14 Xu JM, Wang Y, Ge FJ, Lin L, Liu ZY, Sharma MR, et al. Severe irinotecan-induced toxicity in a patient with UGT1A1 2B7 and UGT1A1 6 polymorphisms. World J Gastroenterol 2013; 19: 3899–903.

15 Cruz JE, Saksena R, Jabbour SK, Nosher JL, Hermes-DeSantis E, Moss RA. The power of genes: a case of unusually severe systemic toxicity after localized hepatic chemoembolization with irinotecan-eluted microspheres for metastatic colon cancer. Ann Pharmacother 2014; 48: 1646–50.

16 Mehotra RK, Bockarie MJ, Zimmerman PA. Prevalence of UGT1A9 and UGT2B7 nonsynonymous single nucleotide polymorphisms in West African, Papua New Guinean, and North American populations. Eur J Clin Pharmacol 2007; 63: 1–8.

17 Deng XY, Wang CX, Wang XD, Bi HC, Chen X, Li JL, et al. Genetic polymorphisms of UGT1A8, UGT1A9, UGT2B7 and ABCC2 in Chinese renal transplant recipients and a comparison with other ethnic populations. Pharmacie 2013; 68: 240–4.

18 Yuan L, Qian S, Xiao Y, Sun H, Zeng S. Homo- and hetero-dimerization of human UDP-glucuronyltransferase 2B7 (UGT2B7) wild type and its allelic variants affect zidovudine glucuronidation activity. Biochem Pharmacol 2015; 95: 58–70.

19 Liu YQ, Yuan LM, Gao ZZ, Xiao YS, Sun HY, Yu LS, et al. Dimerization of human uridine diphosphate glucuronyltransferase allozymes 1A1 and 1A9 alters their quercetin glucuronidation activities. Sci Rep 2016; 6: 23763.

20 De Gregori S, De Gregori M, Ranzani GN, Allegri M, Minella C, Regazzi M. Morphine metabolism, transport and brain disposition. Metab Brain Dis 2012; 27: 1–5.

21 Frances B, Gout R, Monserrat B, Cros J, Zajac JM. Further evidence that morphine-6 beta-glucuronide is a more potent opioid agonist than morphine. J Pharmacol Exp Ther 1992; 262: 25–31.

22 Ouellet DM, Pollack GM. Effect of prior morphine-3-glucuronide exposure on morphine disposition and antinociception. Biochem Pharmacol 1997; 53: 1451–7.